WHO ICTRP trial
An explosive study on add-on effects of ribavirin in sofosbuir and ledipasvir…
JPRN-UMIN000020009 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000020009 |
|---|---|
| Public title | An explosive study on add-on effects of ribavirin in sofosbuir and ledipasvir combination therapy for patients who failed to daclatasvir and asunaprevir combination therapy. |
| Scientific title | An explosive study on add-on effects of ribavirin in sofosbuir and ledipasvir combination therapy for patients who failed to daclatasvir and asunaprevir combination therapy. - SOF/LDV/RBV combination therapy for patients who failed to DAC/ASV therapy |
| Primary sponsor | Hokkaido University Department of Gastroenterology and Hepatology, Graduate School of Medicine, |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Patients with chronic HCV infection, who failed to DCV/ASV therapy |
| Interventions | RBV add-on for 12 weeks |
| Registration date | Mar 12, 2015 |
| Target size | 15 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: